Pediatric Blood & Cancer · 2022 · 12 citations · 10 references
MedicineNeurologyOncologyNeoplasiaNeuro-oncologyPediatric OncologyBrain TumorsNeuro-oncology Clinical TrialsPediatric Brain TumorsPediatric Neuro-oncologyPeripheral Nerve TumorsRadiation TherapyErlotinib TherapyKinase Signaling InhibitorsNeurofibromatosis Type 1Neurofibromatosis-associated TumorsPediatric Neuro-oncology TrialsPlexiform Neurofibroma SurgeryProtein Kinase InhibitorsRas-targeted Therapies
Neurofibromatosis type 1-associated plexiform neurofibromas can cause debilitating symptoms and be life threatening. Treatment options are limited, given their tendency to regrow following surgery and their propensity to transform into malignant tumours following radiation. Selumetinib is an oral selective inhibitor of RAS-mitogen-activated protein kinase (MAPK) 1 and 2, which has shown efficacy for tumour shrinkage/stabilisation and symptom improvement. We report a national case series of 19 children treated with selumetinib. All patients experienced symptom improvement or stabilisation with an acceptable toxicity profile, including those patients previously treated with trametinib. This real-world experience confirms previous trials showing significant clinical benefit for this patient population.
10
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Alan L. Ho, Ravinder K. Grewal, Rébecca Leboeuf et al. · New England Journal of Medicine · 2013 · 829 citations · Full text
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Andrea M. Gross, Pamela L. Wolters, Eva Dombi et al. · New England Journal of Medicine · 2020 · 698 citations · Full text
Medicine, Neurology, Pediatrics +9
Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas
Eva Dombi, Andrea Baldwin, Leigh Marcus et al. · New England Journal of Medicine · 2016 · 665 citations · Full text